Alithya Group inc (ALYAF): Financial results for Q2 2027

Alithya Group inc (ALYAF) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Alithya reports second quarter Fiscal 2027 results Bookings (1) reach $108.2 million, with a Book-to-Bill Ratio (1) of 1.05 Q2-2027 Highlights • Revenues of $103.4 million, down 16.8% year-over-year. 82.6% of revenues were generated from clients which we had in the s

Event · Earnings
Also in this documentBuyback · 5.94M

Facts are quoted from the filing text and checked against it. Details that could not be matched to the text are left out.

Original reporting
Published Nov 13, 2026, 12:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 12:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ALYAF
Bearish
high confidence
Mentioned
$ALYAF
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 6-K
Decision brief

The 30-second read

$ALYAFBearishMed
01

Why it matters

The earnings release provides the first public disclosure of Q2 2027 results, offering fresh data for valuation models.

02

Market read

Earnings miss may trigger short‑term sell‑off; strategic review adds uncertainty.

03

What to watch

Strong bookings and a book‑to‑bill ratio above 1 suggest underlying demand may still be resilient.

Relevance 7/10Novelty 7/10Timing: today

Background

Alithya is a Canadian digital transformation services firm listed on the TSX (ALYA) and trades in the US as ALYAF.

Company-level read

Ticker impact

$ALYAFBearishHigh confidence
Context

Alithya Group inc. filed its Q2 2027 earnings on Form 6‑K, reporting a 16.8% revenue decline and a net loss of $25.0 million.

Expected impact

likely downside as investors price in weaker revenue and margin compression

Evidence & confidence

Revenue fell 16.8% YoY, gross margin dropped 24.1 pts and net loss widened, indicating deteriorating operating performance.

Market effects

Highlights pressure on Canadian tech services sector amid slower client spending.

May weigh on Toronto Stock Exchange tech listings.

Limited; primarily a regional earnings miss.

Counterpoint

If the strategic review leads to a sale or recapitalization, the stock could rally on acquisition speculation.

Key entities

  • Alithya Group inc.

    Canadian digital services provider reporting Q2 2027 results.

  • Scotiabank

    Advising Alithya on its strategic review.

Related articles

Med

Alithya Group inc (ALYAF): Financial results for Q1 2027

Alithya Group inc (ALYAF) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Alithya reports first quarter Fiscal 2027 results Alithya retains Scotiabank as financial advisor in connection with strategic review process Q1-2027 Highlights • Revenues decreased 15.4% to $105.1 million, compared to $124.2 million for the same quarter last year. 7

$NMAXMed

Why Newsmax Stock Popped on Friday

Newsmax (NMAX) shares rose 31% after reporting Q3 revenue of $69M, up 52.5% YoY, and net income of $15.2M. The company cited strong audience engagement and growth in high-margin revenue streams. CEO Christopher Ruddy expects continued growth ahead of the presidential election.

$LUNRMed

What Is Driving Intuitive Machines Stock?

Intuitive Machines (LUNR) shares rose 7.0% on Nov 12, 2026, after reporting Q3 revenue of $269M, beating estimates. The company's loss of $0.10 per share met expectations, while gross margin improved to 26%. Free cash flow turned positive at $33M, a company record. Management raised full-year revenue guidance to $920M-$950M. The stock's performance contrasted with broader industry declines.

$RMIXMedAI 8/10

Suncrete (RMIX) Q3 2026 Earnings Call Transcript

Suncrete (RMIX) reported Q3 2026 revenue of $141M, up 45% QoQ and 163% YoY. Adjusted EBITDA rose 66% QoQ to $22.4M. The company lowered its full-year outlook due to residential construction weakness but remains confident in long-term demand. Acquisition integration is progressing, with North Texas showing margin improvement. Suncrete expects $200M-$250M revenue from 2026 acquisitions in 2027. The company has $206.5M in total liquidity.

$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.